Navigation Links
Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
Date:5/3/2012

s other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.Lexicon Pharmaceuticals, Inc.Selected Financial Data Consolidated Statements of Operations DataThree Months EndedMarch 31,(In thousands, except per share data)20122011(unaudited)Revenues:Collaborative research................................................................ $
52$
516Subscription and license fees...................................................... 14880Total revenues...................................................................... 300596Operating expenses:Research and development, including stock-based compensationof $1,037 and $839, respectively........................................... 23,03723,921Increase in fair value of Symphony Icon, Inc. purchase liability 2,0811,058General and administrative, including stock-based compensationof $681 and $633, respectively.............................................. 4,5654,753Total operating expenses...................................................... 29,6
'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
3. Lexicon Pharmaceuticals to Present at the RBC Healthcare Conference
4. Lexicon to Report Fourth Quarter and Year End 2011 Financial Results on February 22, 2012
5. Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Lexicon Announces Commencement of Rights Offering to Stockholders
7. Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
9. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
10. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
11. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health care ... new IT value-added reseller (VAR) national contracts that expand ... and services at lower costs. These include manufacturer product ... as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... , LAKE FOREST, Ill., Dec. 16 Hospira, ... pharmaceutical and medication delivery company, today announced that it will ... 2009 results and projections for 2010 on Thursday, Feb. 4, ... release its fourth-quarter and full-year 2009 results earlier that morning, ...
... , GREEN BAY, Wis., Dec. ... with DolCas Biotech for the use of super ... multiple EuroPharma formulations. The exclusive distribution territory ... food store channel and professional channel, which includes ...
Cached Medicine Technology:EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3
(Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
(Date:4/17/2014)... by researchers at UC Davis has shown that the ... in cell division, also boosts the mitochondrial activity to ... complex has been shown to perform both jobs. This ... to control cellular energy production, potentially advancing cancer care ... in the journal Developmental Cell . , "These ...
(Date:4/17/2014)... days to find a colored ribbon representing a disease. A ... what color ribbon does one think of with lung cancer?, ... many suffering from the disease, black may be the only ... of lung cancer patients, primarily smokers between the ages of ... the stigma often felt by these patients, the emotional toll ...
(Date:4/17/2014)... study has found that India,s shocking rates of suicide ... who are clinging to tiny smallholdings less than ... such as cotton and coffee, that are highly susceptible ... range of previous case studies that point to a ... the ,liberalisation, of the nation,s economy during the 90s. ...
(Date:4/17/2014)... the leading weapon against the deadly disease could be ... indicating it simply needs to be administered differently. , ... anti-malarial drug chloroquine in treating and preventing the mosquito-bourne ... a million people each year around the world. , ... chloroquine, but research carried out at the Australian National ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Scientists find new way to fight malaria drug resistance 2
... over-the-counter pain killers should carry warnings that they ... comments follow a study by Danish reseacher Gunnar ... British Medical Journal which studied the effect on ... indomethacin (ibuprofen). ,Researchers used prescription //records to ...
... from the University of Chapel Hill have found ... appear to worsen the outcome. ,The study tracked two ... had lower back pain for over six weeks. One group ... that after three months, patients who had initially received the ...
... Pharmaceuticals. Baycol, which was initially approved by the FDA, ... cholesterol by blocking enzymes that are essential in the ... has voluntarily recalled its cholesterol drug Baycol( cerivastatin ) ... deaths. Baycol can cause a muscular side effect called ...
... stimuli also affect the appetite centre of the brain.,It is ... often accompanies pain. People with migraine, for instance, cannot face ... one common linked symptom is nausea. ,Scientists at ... reveal, in a study,// the changes in the brain when ...
... Carolina at Chapel Hill, state about the discovery of how ... The UNC scientists have found a previously unknown ... the genetic messenger known as RNA. When the chemical ... which the information contained in DNA,is converted into functions critical ...
... research has found that young women are much more likely ... which contradicts the stereotype that men are more likely to ... Internal Medicine this week. ,Researchers from Emory, Yale and ... were discharged from hospital after a heart attack. They found ...
Cached Medicine News:
... in gloves, Polymed has become even better. Polymed® ... of regular Polymed with the exciting addition of ... of antioxidants, which are vital to healthy skin. ... powder-free to reduce the potential for latex sensitization. ...
... DRAPE. Soft translucent material ... Latex finger cot with ... base. Full-width 50mm adhesive ... with finger lift for ...
CYSTOSCOPY "T". DRAPE...
Urological Drape Aggressive adhesive with no residue Latex-free finger cot Strong, low-glare matte finish film Non-linting, tear resistant poly release liner...
Medicine Products: